<DOC>
	<DOCNO>NCT01312129</DOCNO>
	<brief_summary>The overarch objective pilot study apply neuroimaging pharmacogenetic tool study alcohol dependence . This propose research provide mechanistic test function genetic variation . The specific aim hypothesis test whether Sulfasalazine , compare placebo , diminish blood-oxygen-level dependent ( BOLD ) response alcohol cue striatum prefrontal cortex ( PFC ) . To test hypothesis , compare Sulfasalazine treatment placebo treatment BOLD difference map contrast alcohol minus control . We also explore whether specific genetic variation influence effect . A double-blind , placebo-controlled 2 ( Medication : Sulfasalazine 1500 mg vs. placebo control ) x 2 ( Cue : Alcohol Cue vs. Control cue ) within-subjects , crossover design use test hypothesis Sulfasalazine reduce BOLD response striatum prefrontal cortex exposure alcohol cue . Twenty alcohol-dependent participant complete two round study medication follow functional magnetic resonance imaging ( fMRI ) scan , complete alcohol cue-exposure task . The order medication condition counterbalance subject randomly assign receive either Sulfasalazine ( 1500 mg ) first session placebo second session one week later ( vice versa ) . This pilot study help determine whether NMDA receptor play role cue-elicited activation key area brain implicate development maintenance substance use disorder . Furthermore , Sulfasalazine reduce cue-elicited activation brain region , hypothesize ; study lay groundwork large trial efficacy Sulfasalazine treatment substance use disorder .</brief_summary>
	<brief_title>Effects Sulfasalazine BOLD Response Alcohol Cues</brief_title>
	<detailed_description>The overarch objective pilot study apply neuroimaging pharmacogenetic tool study alcohol dependence . This propose research provide mechanistic test function genetic variation . The specific aim hypothesis test whether Sulfasalazine , compare placebo , diminish blood-oxygen-level dependent ( BOLD ) response alcohol cue striatum prefrontal cortex ( PFC ) . To test hypothesis , compare Sulfasalazine treatment placebo treatment BOLD difference map contrast alcohol minus control . We also explore whether specific genetic variation influence effect . Several recent study support premise genetic difference may predict treatment outcome . In early study , A G single nucleotide polymorphism ( SNP ; rs1799971 ) mu opiate receptor gene ( OPRM1 ) predict 12 week abstinence treatment alcohol dependence naltrexone ( Oslin et al 2003 ) . The relationship individual least one copy G allele demonstrate low relapse rate long time return heavy drinking treat naltrexone ( Oslin et al 2003 ) . These observation recently replicate extended multisite COMBINE study , individual G allele demonstrate superior outcome treatment naltrexone , combination medication management ( Anton et al 2008 ) . Laboratory study suggest clinical effect may relate great reduction acute reward effect alcohol among individual G allele ( Ray &amp; Hutchison 2007 ) suggest mechanism may relate blunt dopamine release VTA ( Ramchandani et al 2009 ) . In addition , recent study medication ( e.g. , topiramate , olanzapine ) find genetic variable predict treatment outcome ( e.g. , Hutchison et al 2006 ; Hutchison 2008 ; Seneviratne et al 2009 ) . It important note gene treatment interaction limit pharmacological treatment , recent study also suggest genetic variation may predict response psychosocial intervention well ( Feldstein Ewing et al 2009 ; Hutchison et al 2006 ) . We decide evaluate clinical effect Sulfasalazine work date suggest genetic variation downstream function implication glutamate function , specifically cysteine/glutamate exchange glutamate transport , strongly associate BOLD response striatum prefrontal cortex exposure alcohol cue . Sulfasalazine medication well characterize safety profile use treatment inflammatory bowel disease , include ulcerative colitis Crohn 's disease several type arthritis , particularly rheumatoid arthritis many year . Most recently , suggest Sulfasalazine may beneficial effect brain , specifically block N-methyl D-aspartate receptor-mediated excitotoxicity result reduced neuronal death ( Bo Rum Ryu et al , 2003 ) . This pilot study help determine whether NMDA receptor play role cue-elicited activation key area brain implicate development maintenance substance use disorder . Furthermore , Sulfasalazine reduce cue-elicited activation brain region , hypothesize ; study lay groundwork large trial efficacy Sulfasalazine treatment substance use disorder . To end , double-blind , placebo-controlled 2 ( Medication : Sulfasalazine 1500 mg vs. placebo control ) x 2 ( Cue : Alcohol Cue vs. Control cue ) within-subjects , crossover design use test hypothesis Sulfasalazine reduce BOLD response striatum prefrontal cortex exposure alcohol cue . Twenty alcohol-dependent participant complete two round study medication follow fMRI scan , complete alcohol cue-exposure task . The order medication condition counterbalance subject randomly assign receive either Sulfasalazine ( 1500 mg ) first session placebo second session one week later ( vice versa ) .</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Sulfasalazine</mesh_term>
	<criteria>2155 year age Alcohol Dependence Medical MRI Contraindications Pregnancy Allergy Sulfa medication</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Alcohol</keyword>
	<keyword>Sulfasalazine</keyword>
</DOC>